Get startedLog in
    Picture of Clarity Pharmaceuticals logo

    CU6 — Clarity Pharmaceuticals News Story

    0.000.00%
    au flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapSucker Stock
    All News

    Brief: Clarity's Theranostic Prostate Cancer Trial Advances To Multi-Dose Phase

    Picture of Clarity Pharmaceuticals logoClarity Pharmaceuticals
    15/03/2024 13:04
    March 15 (Reuters) - Clarity Pharmaceuticals Ltd
 CU6.AX :
    * CLARITY'S THERANOSTIC PROSTATE CANCER TRIAL ADVANCES TO
MULTI-DOSE PHASE
    * CLARITY PHARMACEUTICALS LTD - NO DOSE LIMITING TOXICITIES
(DLTS)
HAVE BEEN REPORTED IN COHORT 3 TO DATE
    * CLARITY PHARMACEUTICALS - OVERALL SAFETY REVIEW OF ALL
COHORTS
1, 2 AND 3 (4, 8 AND 12GBQ SINGLE DOSE, RESPECTIVELY) SHOWED A
FAVORABLE SAFETY PROFILE

Source text for Eikon:  ID:nPn1DPJl0a 
Further company coverage:  CU6.AX 

 ((reuters.briefs@thomsonreuters.com;))

    Recent news on Clarity Pharmaceuticals

    See all news